Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201.

Christian KretzerPaul M JordanRossella BilanciaAntonietta RossiTuğçe Gür Maz Erden BanogluUlrich S SchubertOliver Werz

Published in: Journal of inflammation research (2022)

BRP-201 acts as FLAP antagonist but also as 12/15-LOX activator switching formation of pro-inflammatory LTs toward inflammation-resolving SPM, which reflects a beneficial pharmacological profile for intervention in inflammation.

Keyphrases

oxidative stress
randomized controlled trial
breast reconstruction
palliative care
signaling pathway
soft tissue
binding protein
anti inflammatory
inflammatory response
small molecule
low density lipoprotein